Phase 2 Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older at the time of agreeing to take part
- People who have been diagnosed with a type of blood cancer called Acute Myeloid Leukemia (AML), specifically a non-M3 subtype, as defined by World Health Organization (WHO) 2016 guidelines
- People whose general health and ability to carry out daily activities meets a certain minimum level (confirm with trial site)
- People who are currently being treated with a combination of medications called HMA (either azacitidine or decitabine) plus venetoclax as their first treatment for AML, and whose disease has gone into remission with no detectable cancer cells found by a sensitive test called Multiparameter Flow Cytometry
- People who started their current treatment within the last 12 months
- People who are not suitable for, or who have chosen not to have, a stem cell transplant from a donor
- People who are willing and able to sign a consent form agreeing to take part
- People who are able to follow the visit schedule and other requirements of the study
- People who are able to provide bone marrow samples (taken by a procedure called a bone marrow aspirate and biopsy) during the screening process
Who may not be able to join:
- People who have received other chemotherapy or experimental (not commercially available) cancer treatments within the past 28 days or within 5 half-lives of those treatments (note: a medication called hydroxyurea taken before achieving remission is allowed)
- People with a serious or uncontrolled medical condition, such as an active infection, heart failure, unstable chest pain, irregular heart rhythms, or a mental health or social situation that could make it difficult to safely participate (note: well-controlled infections or other conditions being managed with long-term treatment may still be allowed)
- People whose cancer was found to have a specific gene change called a TP53 mutation at the time of their original diagnosis
- People whose AML has spread outside the bone marrow — for example, to the nervous system, formed tumours in other parts of the body, or affected the skin — and who need treatment directed at those areas at the time of enrolment
- People who are pregnant
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Onyee Chan, MD, Moffitt Cancer Center
Phone: 813-745-6138
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Rates of Complete Response (CR)/Complete Response with incomplete hematologic recovery (CRi)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.